Repligen vs Bio-Techne
RGEN and TECH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RGEN and TECH compare
Repligen and Bio-Techne are about the same size, with market caps of $10.0B and $11.4B.
Repligen grew revenue faster over the last twelve months (13.8% versus −0.38% for Bio-Techne).
Bio-Techne pays a dividend yielding 0.44%; Repligen does not pay one.
Bio-Techne scores higher on the StockData Score (12 against 7 for Repligen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RGEN | TECH |
|---|---|---|
| Size and price | ||
| Market cap | $10.0B | $11.4B |
| Share price | $176.94 | $72.66 |
| Change, 1 year | 19.2% | 17.2% |
| Change, 5 years | −33.7% | −41.6% |
| Beta (5Y) | 1.50 | 1.08 |
| Employees | 2,000 | 3,000 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 62.6× |
| P/S | 12.4× | 9.4× (better) |
| P/B | 4.8× (better) | 5.4× |
| EV/EBITDA | 94.9× | 32.4× (better) |
| P/FCF | 93.6× | 43.3× (better) |
| FCF yield | 1.1% | 2.3% (better) |
| Fair value | $79.82 | $52.72 |
| Margin of safety | −122% | −37.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.8% (better) | −0.38% |
| Revenue growth, 5Y average | 15.0% (better) | 5.5% |
| Net income growth (TTM) | −779% | – |
| EPS growth (TTM) | – | 152% |
| EPS growth, 5Y average | −5.0% | 5.9% (better) |
| Profitability | ||
| Gross margin | 53.5% | 65.8% (better) |
| Operating margin | 2.3% | 20.7% (better) |
| Net margin | −1.5% | – |
| FCF margin | 13.2% | 21.7% (better) |
| Return on equity | −0.57% | – |
| Return on invested capital | 0.71% | 9.2% (better) |
| Financial health | ||
| Debt / equity | – | 0.09 |
| Net debt / EBITDA | – | −0.19 |
| Interest coverage | 0.8× | 26.2× (better) |
| Current ratio | 9.88 (better) | 4.55 |
| Altman Z-score | 8.14 | 15.97 (better) |
| Piotroski F-score | 7 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 0.44% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 0.37% |
| Shareholder yield | 0.00% | 0.81% (better) |
| Ownership | ||
| Held by institutions | 117% | 112% |
| Held by insiders | 0.67% | 0.35% |
| Insider net buying, 12 months | −$14.2M | −$437K (better) |
| Superinvestors holding | 2 | 4 (better) |
| Short interest, % of float | 13.5% | 4.7% |
Go deeper
- RGEN stock overview
- RGEN income statement
- RGEN valuation and score
- TECH stock overview
- TECH income statement
- TECH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.